Recent studies in pancreatic cancer treatment demonstrate that targeting tumor-associated MUC1 (tMUC1) with the monoclonal antibody TAB004 overcomes anoikis resistance by specifically binding to tMUC1, reducing cancer cell viability and promoting its degradation (17). This evidence concerns the gene MUC1 and cancer.